Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D

验证了GAIA平台的技术实力，并加强全球共同开发的努力，包括与Lilly Catalyze360-ExploR&D的现有合作伙伴关系。

Funds to accelerate Alzheimer's and immune disease drug development, expanding GAIA-based pipeline

资金将用于加速阿尔茨海默病和免疫疾病药物的开发，扩展基于GAIA的管线。

SEOUL, South Korea

韩国，首尔

,

，

July 14, 2025

2025年7月14日

/PRNewswire/ -- The Series B round saw strong participation from both existing and new investors, demonstrating high industry confidence in Illimis Therapeutics' vision and technology. Eight existing investors, including DSC Investment, Woori Venture Partners, Korea Development Bank, Aju IB Investment, Quad Asset Management, Company K Partners, GS Ventures, and Dayli Partners, reaffirmed their commitment.

/PRNewswire/ -- B轮融资获得了现有投资者和新投资者的强烈参与，显示出业界对Illimis Therapeutics的愿景和技术的高度信心。包括DSC Investment、Woori Venture Partners、韩国开发银行、Aju IB Investment、Quad Asset Management、Company K Partners、GS Ventures和Dayli Partners在内的八家现有投资者再次确认了他们的承诺。

They were joined by ten new investors: LB Investment, TS Investment, Shinhan Venture Investment, S&S Investment, Hana Ventures, Maple Investment Partners, A Ventures, IMM Investment, Schmidt, and Industrial Bank of Korea..

他们还迎来了十位新投资者：LB Investment、TS Investment、Shinhan Venture Investment、S&S Investment、Hana Ventures、Maple Investment Partners、A Ventures、IMM Investment、Schmidt 以及韩国产业银行。

The proceeds will be used to accelerate the development of GAIA-based Alzheimer's Disease therapeutics, expand its target indications to various immune disorders, and broaden its pipeline of potential blockbuster drug candidates. The company is actively pursuing early-stage collaborations with global pharmaceutical companies and research institutions to add value to internal programs..

这笔资金将用于加速基于GAIA的阿尔茨海默病治疗药物的开发，将其目标适应症扩展到各种免疫疾病，并拓宽其潜在重磅药物候选管线。该公司正在积极寻求与全球制药公司和研究机构的早期合作，以为内部项目增加价值。

'In the evolving landscape of new drug development where the limitations of existing medications are continually being overcome, Illimis' differentiated platform technology is expected to emerge as a next-generation treatment option for neuro-immune diseases with high unmet medical needs,' said

“在新药开发不断发展的格局中，现有药物的局限性正在不断被克服，Illumis差异化的平台技术有望成为满足神经免疫疾病高未满足医疗需求的下一代治疗选择，”

Yohan Kim

金曜汉

, Senior Managing Director at DSC Investment, who led this investment round and has also been appointed to the board of directors.

，DSC投资公司的高级董事总经理，他领导了这轮融资并已加入董事会。

Jiwoong Chun

全智雄

, Managing Director at Woori Venture Partners and an active board member and investor since the company's inception, added, 'Illimis is a prime example of a smart Korean biotech unlocking global markets with proprietary innovation and capital efficiency.'

“,伍丽风险投资公司的总经理，自公司成立以来一直担任董事会成员并积极参与投资，补充道：‘Illimis是智能韩国生物技术的典型例子，通过自主创新增加资本效率开拓全球市场。’”

Illimis has recently been selected for the '2025 Global Joint Research to Defeat Dementia' led by the Ministry of Health and Welfare and the Korean Dementia Research Center, securing

伊里米斯最近被选为由韩国保健福祉部和韩国痴呆症研究中心主导的“2025年全球联合研究战胜痴呆”项目，确保了相关支持。

KRW 2.2 million

韩元 220万

(

(

$1.6 million

160万美元

) in funding over three years, further validating its technological capabilities. This initiative aims to develop Alzheimer's therapeutics through global joint research leveraging the GAIA platform, positioning Illimis at the center of international collaboration.

）为期三年的资助，进一步验证了其技术能力。该计划旨在通过利用GAIA平台进行全球联合研究来开发阿尔茨海默病治疗药物，使Illimis成为国际合作的核心。

Furthermore, in

此外，在

October 2024

2024年10月

, Illimis partnered with Eli Lilly and Company (Lilly)'s Catalyze360-ExploR&D, a core pillar of external innovation at Lilly dedicated to deploying world-leading research and development capabilities and scientific know-how to accelerate partner science. Under this research collaboration, Illimis and Lilly have been cooperating to advance the platform construct for applications in neurodegenerative diseases.

，Illimis与礼来公司（Lilly）的Catalyze360-ExploR&D建立了合作关系，这是礼来外部创新的核心支柱，致力于运用世界领先的研发能力和科学知识，加速合作伙伴的科学研究。在此研究合作框架下，Illimis与礼来一直在共同努力推进该平台在神经退行性疾病中的应用构建。

Illimis has also strengthened its global pharma collaborations by winning the 2023 BMS Innovation Square Challenge and joining Johnson & Johnson's global incubator network as a member company of JLABS Singapore in 2024..

Illimis还通过赢得2023年BMS创新广场挑战赛，并于2024年作为JLABS新加坡的成员公司加入强生公司的全球孵化器网络，进一步加强了其全球制药合作。

To further enhance its drug development competitiveness, Illimis Therapeutics operates a Scientific Advisory Board (SAB). The SAB includes Dr.

为了进一步提升其药物开发的竞争力，Illimis Therapeutics 设立了科学顾问委员会（SAB）。该委员会包括 Dr.

Greg Lemke

格雷格·莱姆克

, Emeritus Professor at the Salk Institute and a world-renowned expert in TAM Biology, and Dr.

，索尔克研究所的名誉教授，TAM生物学领域世界知名的专家，以及博士。

Morgan Sheng

摩根·盛

, a leading neuroscientist at the Broad Institute who previously served as Vice President of Neuroscience at Genentech. These experts provide strategic guidance across the entire R&D lifecycle, including pipeline development, candidate discovery, clinical trial design, etc., and play a pivotal role in strengthening Illimis Therapeutics' global partnerships..

，他是布罗德研究所的领先神经科学家，之前曾担任基因泰克公司神经科学副总裁。这些专家在整个研发生命周期内提供战略指导，包括管线开发、候选药物发现、临床试验设计等，并在加强Illimis Therapeutics的全球合作伙伴关系中发挥关键作用。

'This investment, government grants, and partnership with Lilly will enable us to accelerate our efforts to conquer diseases with high unmet clinical needs based on a comprehensive understanding of TAM biology and establish global leadership in TAM biology,' said

“这项投资、政府拨款以及与礼来公司的合作将使我们能够加快努力，基于对TAM生物学的全面理解来攻克具有高度未满足临床需求的疾病，并在TAM生物学领域确立全球领导地位，”

Sanghoon Park

朴尚勋

, CEO of Illimis Therapeutics. 'We will continue to focus on innovative new drug development centered around the GAIA platform and provide tangible treatment options to patients worldwide through early R&D collaboration models.'

`, Illimis Therapeutics首席执行官。‘我们将继续专注于围绕GAIA平台的创新新药开发，并通过早期研发合作模式为全球患者提供切实可行的治疗选择。’`

About Illimis Therapeutics

关于Illimis治疗学

Illimis Therapeutics is a pioneering biotechnology company at the forefront of developing innovative therapies for challenging central nervous system (CNS) and immune-related diseases. The company's core strength lies in its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform. This cutting-edge platform is designed to harness the therapeutic potential of TAM (Tyro3, Axl, Mer) receptor biology, a critical pathway involved in regulating inflammation and immune responses.

伊里米斯治疗公司是一家处于开发创新疗法前沿的先锋生物技术公司，专注于应对中枢神经系统（CNS）和免疫相关疾病的挑战。公司的核心优势在于其专有的GAIA（Gas6介导的抗炎适配器）平台。这一尖端平台旨在利用TAM（Tyro3、Axl、Mer）受体生物学的治疗潜力，这是调控炎症和免疫反应的关键通路。

The company's lead pipeline, ILM01 for the treatment of Alzheimer's Disease, is entering into the preclinical stage in the second half of 2025 and expecting to submit an IND by the end of 2027. For more information, visit .

该公司主导的阿尔茨海默病治疗管线ILM01将于2025年下半年进入临床前阶段，并预计在2027年底前提交IND申请。欲了解更多信息，请访问。

https://illimistx.com/en

https://illimistx.com/zh

.

。

SOURCE Illimis Therapeutics

源伊里米斯治疗学

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗？

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用